Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taselisib - Genentech/Chugai Pharmaceutical

Next Previous
X
Search
Drug Profile

Taselisib - Genentech/Chugai Pharmaceutical

Alternative Names: GDC 0032; RG-7604

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; Netherlands Cancer Institute
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Benzazepines; Oxazepines; Pyrazoles; Small molecules; Triazoles
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 01 May 2022 The Netherlands Cancer Institute and Genentech completes a phase I/II trial in Breast cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in France, Netherlands, Spain and United Kingdom (NCT02285179)
  • 24 Sep 2021 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO)
  • 24 Sep 2021 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top